IL258862B - N-[2-(1-Benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperidine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 antagonists for the treatment of neurological diseases - Google Patents
N-[2-(1-Benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperidine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 antagonists for the treatment of neurological diseasesInfo
- Publication number
- IL258862B IL258862B IL258862A IL25886218A IL258862B IL 258862 B IL258862 B IL 258862B IL 258862 A IL258862 A IL 258862A IL 25886218 A IL25886218 A IL 25886218A IL 258862 B IL258862 B IL 258862B
- Authority
- IL
- Israel
- Prior art keywords
- benzylpiperidin
- pyrazin
- piperazine
- antagonists
- ethyl
- Prior art date
Links
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title 1
- NTEFDRIAFGEYBB-UHFFFAOYSA-N N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-pyrazin-2-ylpiperazine-1-carboxamide Chemical class C(C1=CC=CC=C1)N1CCC(CC1)CCNC(=O)N1CCN(CC1)C1=NC=CN=C1 NTEFDRIAFGEYBB-UHFFFAOYSA-N 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252179P | 2015-11-06 | 2015-11-06 | |
| US201662275708P | 2016-01-06 | 2016-01-06 | |
| PCT/US2016/060659 WO2017079641A1 (en) | 2015-11-06 | 2016-11-04 | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL258862A IL258862A (en) | 2018-06-28 |
| IL258862B true IL258862B (en) | 2021-02-28 |
Family
ID=57349137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL258862A IL258862B (en) | 2015-11-06 | 2018-04-23 | N-[2-(1-Benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperidine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 antagonists for the treatment of neurological diseases |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11033539B2 (OSRAM) |
| EP (1) | EP3371164B1 (OSRAM) |
| JP (2) | JP6917989B2 (OSRAM) |
| KR (1) | KR20180073685A (OSRAM) |
| CN (1) | CN108349936B (OSRAM) |
| AU (1) | AU2016348524B2 (OSRAM) |
| BR (1) | BR112018008630A2 (OSRAM) |
| CA (1) | CA3001873A1 (OSRAM) |
| CL (1) | CL2018001217A1 (OSRAM) |
| CO (1) | CO2018004800A2 (OSRAM) |
| ES (1) | ES2915266T3 (OSRAM) |
| HK (1) | HK1253029A1 (OSRAM) |
| IL (1) | IL258862B (OSRAM) |
| MA (1) | MA43168A (OSRAM) |
| MX (1) | MX386148B (OSRAM) |
| MY (1) | MY194461A (OSRAM) |
| PE (1) | PE20181010A1 (OSRAM) |
| PH (1) | PH12018500940A1 (OSRAM) |
| SA (1) | SA518391518B1 (OSRAM) |
| SG (1) | SG11201803757UA (OSRAM) |
| TN (1) | TN2018000130A1 (OSRAM) |
| WO (1) | WO2017079641A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050083T2 (hu) | 2015-11-06 | 2020-11-30 | Hoffmann La Roche | Indolin-2-on származékok |
| SG11201803757UA (en) * | 2015-11-06 | 2018-06-28 | Neurocrine Biosciences Inc | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
| WO2019032654A1 (en) | 2017-08-08 | 2019-02-14 | Vanderbilt University | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
| WO2019079410A1 (en) | 2017-10-17 | 2019-04-25 | Vanderbilt University | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
| CA3079617A1 (en) | 2017-10-20 | 2019-04-25 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019089676A1 (en) | 2017-10-31 | 2019-05-09 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| EP3732163A4 (en) | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS |
| CA3090130A1 (en) * | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| PE20251292A1 (es) | 2018-03-08 | 2025-05-14 | Incyte Corp | Compuestos diolicos de aminopirazina como inhibidores de pi3k-gamma |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020051153A1 (en) | 2018-09-04 | 2020-03-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine m1 receptor antagonists |
| CN119241444A (zh) * | 2019-06-17 | 2025-01-03 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
| JP2022549227A (ja) * | 2019-09-17 | 2022-11-24 | バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ | 医学的障害の治療における使用のための置換された飽和および不飽和ｎ－複素環式カルボキサミドおよび関連化合物 |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| ES2983860T3 (es) | 2019-12-06 | 2024-10-25 | Neurocrine Biosciences Inc | Antagonistas del receptor muscarínico 4 y métodos de uso |
| CN111072551A (zh) * | 2019-12-30 | 2020-04-28 | 上海睿瓦科技有限公司 | 催化氢化一步法制取哌啶胺的方法 |
| EP4100410A1 (en) * | 2020-02-05 | 2022-12-14 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| WO2022156708A1 (en) * | 2021-01-20 | 2022-07-28 | Jacobio Pharmaceuticals Co., Ltd. | Parp7 enzyme inhibitor |
| KR20240019340A (ko) * | 2021-06-11 | 2024-02-14 | 뉴로내슨트, 아이엔씨. | 헤테로시클릭 유형의 친유성 소분자 치료의 지질 제제를 위한 방법 및 조성물 |
| WO2023010078A1 (en) * | 2021-07-30 | 2023-02-02 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| KR20250116664A (ko) * | 2022-11-16 | 2025-08-01 | 번위 테라퓨틱스 인코포레이티드 | Tyk2의 저해제 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622976A (en) * | 1991-12-31 | 1997-04-22 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| GB9313201D0 (en) * | 1993-06-25 | 1993-08-11 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| US5700801A (en) * | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| TR200001399T2 (tr) * | 1997-11-18 | 2000-11-21 | Teijin Limited | Siklik amin türevleri ve ilaç olarak kullanımları. |
| DE60023878T2 (de) * | 1999-05-18 | 2006-07-20 | Teijin Ltd. | Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen |
| AU5786300A (en) * | 1999-09-22 | 2001-04-24 | Schering Corporation | Muscarinic antagonists |
| KR100708247B1 (ko) * | 1999-12-08 | 2007-04-16 | 데이진 가부시키가이샤 | 고리형 아민 ｃｃｒ５ 리셉터 길항제 |
| US6410566B1 (en) * | 2000-05-16 | 2002-06-25 | Teijin Limited | Cyclic amine derivatives and their use as drugs |
| WO2003062234A1 (en) | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Quinoxaline compounds |
| US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| AU2003300902A1 (en) * | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Piperidine derivatives as CCR5 antagonists |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| EP1904446A2 (en) * | 2005-07-11 | 2008-04-02 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
| WO2007075629A2 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| EP1997805A1 (en) * | 2007-06-01 | 2008-12-03 | Commissariat à l'Energie Atomique | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans |
| JP2013028538A (ja) * | 2009-11-13 | 2013-02-07 | Dainippon Sumitomo Pharma Co Ltd | 新規アミド誘導体 |
| EA027800B1 (ru) | 2011-11-25 | 2017-09-29 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1 |
| US20150259649A1 (en) * | 2012-11-08 | 2015-09-17 | Emory University | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto |
| HK1207317A1 (en) * | 2012-11-20 | 2016-01-29 | 霍夫曼-拉罗奇有限公司 | Substituted 1,6-naphthyridines |
| US10179770B2 (en) | 2013-03-18 | 2019-01-15 | Genoscience Pharma | Quinolines derivatives as novel anticancer agents |
| JP6272832B2 (ja) | 2013-04-04 | 2018-01-31 | 武田薬品工業株式会社 | 複素環化合物 |
| US9611223B2 (en) * | 2013-09-11 | 2017-04-04 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| US9745271B2 (en) * | 2014-03-20 | 2017-08-29 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| SG11201803757UA (en) * | 2015-11-06 | 2018-06-28 | Neurocrine Biosciences Inc | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
-
2016
- 2016-11-04 SG SG11201803757UA patent/SG11201803757UA/en unknown
- 2016-11-04 KR KR1020187015620A patent/KR20180073685A/ko not_active Ceased
- 2016-11-04 ES ES16798333T patent/ES2915266T3/es active Active
- 2016-11-04 MA MA043168A patent/MA43168A/fr unknown
- 2016-11-04 PE PE2018000730A patent/PE20181010A1/es unknown
- 2016-11-04 MX MX2018005215A patent/MX386148B/es unknown
- 2016-11-04 EP EP16798333.7A patent/EP3371164B1/en active Active
- 2016-11-04 HK HK18112407.2A patent/HK1253029A1/zh unknown
- 2016-11-04 WO PCT/US2016/060659 patent/WO2017079641A1/en not_active Ceased
- 2016-11-04 CN CN201680064834.6A patent/CN108349936B/zh active Active
- 2016-11-04 BR BR112018008630A patent/BR112018008630A2/pt not_active IP Right Cessation
- 2016-11-04 CA CA3001873A patent/CA3001873A1/en not_active Abandoned
- 2016-11-04 JP JP2018522553A patent/JP6917989B2/ja active Active
- 2016-11-04 AU AU2016348524A patent/AU2016348524B2/en not_active Ceased
- 2016-11-04 TN TNP/2018/000130A patent/TN2018000130A1/en unknown
- 2016-11-04 US US15/773,915 patent/US11033539B2/en active Active
- 2016-11-04 MY MYPI2018000570A patent/MY194461A/en unknown
-
2018
- 2018-04-23 IL IL258862A patent/IL258862B/en active IP Right Grant
- 2018-05-02 PH PH12018500940A patent/PH12018500940A1/en unknown
- 2018-05-04 CO CONC2018/0004800A patent/CO2018004800A2/es unknown
- 2018-05-04 CL CL2018001217A patent/CL2018001217A1/es unknown
- 2018-05-05 SA SA518391518A patent/SA518391518B1/ar unknown
-
2021
- 2021-01-05 JP JP2021000354A patent/JP2021050243A/ja not_active Withdrawn
- 2021-04-26 US US17/239,726 patent/US20210338653A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX386148B (es) | 2025-03-18 |
| CL2018001217A1 (es) | 2018-08-03 |
| TN2018000130A1 (en) | 2019-10-04 |
| SG11201803757UA (en) | 2018-06-28 |
| MY194461A (en) | 2022-11-30 |
| SA518391518B1 (ar) | 2021-06-13 |
| KR20180073685A (ko) | 2018-07-02 |
| JP2018531981A (ja) | 2018-11-01 |
| US20180325887A1 (en) | 2018-11-15 |
| CA3001873A1 (en) | 2017-05-11 |
| MA43168A (fr) | 2018-09-12 |
| MX2018005215A (es) | 2018-08-01 |
| CN108349936A (zh) | 2018-07-31 |
| ES2915266T3 (es) | 2022-06-21 |
| EP3371164A1 (en) | 2018-09-12 |
| EP3371164B1 (en) | 2022-03-16 |
| PH12018500940A1 (en) | 2018-12-17 |
| JP6917989B2 (ja) | 2021-08-11 |
| CO2018004800A2 (es) | 2018-10-31 |
| CN108349936B (zh) | 2021-10-01 |
| US20210338653A1 (en) | 2021-11-04 |
| BR112018008630A2 (pt) | 2018-10-30 |
| PE20181010A1 (es) | 2018-06-26 |
| JP2021050243A (ja) | 2021-04-01 |
| HK1253029A1 (zh) | 2019-06-06 |
| IL258862A (en) | 2018-06-28 |
| AU2016348524A1 (en) | 2018-05-17 |
| WO2017079641A1 (en) | 2017-05-11 |
| AU2016348524B2 (en) | 2021-01-28 |
| US11033539B2 (en) | 2021-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258862A (en) | Derivatives Ann .- [2- (1-Benzylphipridine-4-yl) ethyl] -4- (Pirazine-2-yl) -pipridine-1-carboxamide and compounds related as muscarinic receptor 4 antagonists for the treatment of neurological diseases | |
| SI3097098T1 (sl) | Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina | |
| IL246875A0 (en) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease | |
| IL280052A (en) | Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidine-4-yl)methyl)isoindoline-1-one for the treatment of schizophrenia | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| NZ725492A (en) | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders | |
| HUE051693T2 (hu) | 5-Klór-N4-[2-(dimetilfoszforil)-fenil]-N2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)-piperidin-1-il] -pirimidin-2,4-diamin kristályos formái | |
| IL291665A (en) | Inhibitors of receptor interaction with protein kinase i for the treatment of disease | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| IL273396A (en) | 4-[[(7-aminopyrazolo[5,1-A]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | |
| IL263161B (en) | New compounds for the treatment of parasitic diseases | |
| IL255937B (en) | Heterocyclic compounds 3,3-difluoropiperidine carbamate as nr2b nmda receptor antagonists | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| IL249428A0 (en) | A polymorphic form of n-[2-(6 fluoro-lh-indol-3-yl)ethyl]-3-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| HK40002410A (en) | Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain | |
| AU2016900635A0 (en) | Inhibitors of beta-arrestin-Neurokinin 1 Receptor Interactions for the Treatment of Pain | |
| TH148816A (th) | อนุพันธ์ฟิวส์เอดแอโซล |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |